This is a preview of subscription content, log in via an institution to check access.
Notes
US dollars
$39 900 per QALY
Reference
Shi Q, et al. The cost-effectiveness of a NSCLC patient assistance program for pemetrexed maintenance therapy in People's Republic of China. ClinicoEconomics and Outcomes Research 2017: 99-106, No. 9, 3 Feb 2017. Available from: URL: https://doi.org/10.2147/CEOR.S119818
Rights and permissions
About this article
Cite this article
Pemetrexed cost effective with assistance program in China. PharmacoEcon Outcomes News 772, 30 (2017). https://doi.org/10.1007/s40274-017-3778-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3778-1